Study Flags Autoimmune Concerns with GLP-1 Use
Patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may face an increased risk of developing certain autoimmune diseases compared with those on dipeptidyl peptidase-4 inhibitors (DPP-4is), according to new real-world evidence from a large U.S. cohort.